Postop Pain Management in Pituitary Tumour Patients

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Pituitary, Pain, Postoperative

In brief

To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.

Key facts

Study ID

NCT06353529

Run by

Hamilton Health Sciences Corporation

People needed

108

Starts

2024-11-25

Expected to finish

2026-07-01

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult patients (18 yrs or older)
• undergoing endonasal pituitary adenoma resection

You may not qualify if…

• Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs
• contraindications to the performance of SPGB such as known allergy to used medications
• chronic alcohol abuse
• uncontrolled systemic arterial hypertension
• severe kidney or liver diseases
• cardiomyopathies or sustained cardiac arrhythmias (permanent paroxystic atrial fibrillation or other sustained supraventricular rhythmic anomalies)

Where it is running

• Hamilton General Hospital — Hamilton, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.